Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

Kazuma Oyama, Itamar Raz, Avivit Cahn, Julia Kuder, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. Mcguire, John P.H. Wilding, Kyong Soo Park, Assen Goudev, Rafael Diaz, Jindřich Špinar, Ingrid A.M. Gause-Nilsson, Ofri Mosenzon, Marc S. Sabatine, Stephen D. Wiviott